Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Ba2bd3820a938d91b02b4ce2b4b2cf179> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Ba2bd3820a938d91b02b4ce2b4b2cf179 NCIT_P378 "NCI" @default.
- Ba2bd3820a938d91b02b4ce2b4b2cf179 type Axiom @default.
- Ba2bd3820a938d91b02b4ce2b4b2cf179 annotatedProperty IAO_0000115 @default.
- Ba2bd3820a938d91b02b4ce2b4b2cf179 annotatedSource NCIT_C189826 @default.
- Ba2bd3820a938d91b02b4ce2b4b2cf179 annotatedTarget "A peptide-drug conjugate (PDC) of paclitaxel with an inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. Upon administration of paclitaxel-conjugated CXCR4 peptide antagonist MB1707, the CXCR4 inhibitor moiety binds to the chemokine receptor CXCR4 expressed on tumor cells, thereby preventing CXCR4 binding to its ligand, stromal derived factor-1 (SDF-1), and subsequent receptor activation. This may result in decreased tumor cell proliferation and migration. In addition, paclitaxel binds to tubulin inside CXCR4-expressing tumor cells and inhibits the disassembly-assembly dynamics of microtubules, resulting in cell cycle arrest and cell death. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types. By targeting CXCR4-expressing tumor cells specifically, paclitaxel's efficacy is increased while minimizing systemic toxiciy." @default.